Constant Therapeutics
Phase 2Constant Therapeutics LLC is a private biopharmaceutical company developing peptide and small molecule drugs. clinical stage company developing Mas receptor agonists for treatment of COVID-19, CNS, and rare disorders. Its lead drug candidate, TXA127, is a pharmaceutical formulation of the natural hu
Market Cap
Private
Pipeline
6
drug candidates
Patents
—
Publications
—
Private Company
Total funding raised: $5.5M
About
Constant Therapeutics LLC is a private biopharmaceutical company developing peptide and small molecule drugs. clinical stage company developing Mas receptor agonists for treatment of COVID-19, CNS, and rare disorders. Its lead drug candidate, TXA127, is a pharmaceutical formulation of the natural hu
RNA & Gene TherapySmall Molecules
Pipeline
66 drugs in pipeline
| Drug | Indication | Stage | Watch |
|---|---|---|---|
| TXA127 + Placebo | Lymphoma, Non-Hodgkin | Phase 2 | |
| Angiotensin 1-7 | COVID-19 | Phase 2 | |
| talfirastide | DMD-Associated Dilated Cardiomyopathy | Phase 2 | |
| TXA127 + Placebo | COVID-19 | Phase 2 | |
| talfirastide + Placebo | Ischemic Stroke | Phase 2 |
Funding History
2Total raised:$5.5M
Seed$3MNov 15, 2021
Grant$2.5MMar 15, 2020